Company Profile
Incyte Stock Price, News & Analysis
- Ticker:
- INCY
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Wilmington, Delaware
Stock performance
118.38 USD (-1.19%)
Close
Last updated: August 6, 2026
18.4B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, INCY closed down 1.19% at $118.38. No new same-company headline was identified in the current news window.
Company overview
Business overview
Incyte is a biopharmaceutical company focused on hematology, oncology, and inflammation. Its business combines a commercial base with a pipeline that continues to produce new opportunities in immunology and cancer.
Geographic Base and Sector Classification
Headquartered in Wilmington, Delaware and listed on NASDAQ, Incyte is a U.S.-based biotech with meaningful global commercial and development exposure. It sits in specialty biopharma rather than general healthcare.
Business Model Characteristics
The company generates value through marketed products, R&D, and pipeline expansion across oncology and inflammatory disease. Investors track revenue durability, new data, and whether the next wave of programs can keep replacing mature growth.
Position Within the Biotechnology Landscape
Incyte is a well-established biotech name with enough commercial scale to soften pure binary risk, but it still reacts to clinical data and label expansion. It sits in a strong middle ground between mature pharma and high-volatility development biotech.
Future catalysts
Incyte’s near-term catalysts are Opzelura growth, povorcitinib readouts, and any label-expansion or pipeline update in dermatology and oncology. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Incyte (INCY)?
Incyte (INCY) most recently closed at 118.38 USD, a -1.19% move versus the previous session.
What is the market cap of Incyte (INCY)?
Incyte currently has a market capitalization of 18.4B USD on BioPharmSignal.
What does Incyte do?
Incyte is a biopharmaceutical company focused on hematology, oncology, and inflammation. Its business combines a commercial base with a pipeline that continues to produce new opportunities in immunology and cancer.
On which exchange is INCY stock listed?
Incyte (INCY) is associated with NASDAQ, Wilmington, Delaware, Biopharma.
What is povorcitinib?
Incyte’s near-term catalysts are Opzelura growth, povorcitinib readouts, and any label-expansion or pipeline update in dermatology and oncology.
Which conditions is Incyte targeting with povorcitinib?
Incyte is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Incyte describe recent progress with povorcitinib?
Incyte’s near-term catalysts are Opzelura growth, povorcitinib readouts, and any label-expansion or pipeline update in dermatology and oncology.
What is Incyte?
Incyte is a biopharmaceutical company focused on hematology, oncology, and inflammation.